Celularity Inc., a cellular medicine company, has entered into a collaboration agreement with BlueSphere Bio (BSB).?
Celularity will leverage its manufacturing capabilities to produce BSB’s T cell receptor (TCR) T cell therapies.?
This partnership will focus on manufacturing and quality control at Celularity’s New Jersey facility for BSB’s therapies, including a treatment for Acute Myelogenous Leukemia (AML).?
The collaboration allows BSB to advance its assets to clinical trials more affordably while retaining control over processes.?
Both CEOs express excitement about the collaboration, highlighting Celularity’s manufacturing infrastructure and BSB’s novel cell therapies.
Find out more details in our latest podcast episode:
